# Changelog

All notable changes to this project's Product Foundation will be documented in this file.

## [Version 1.0] - 2026-07-05

### Added
*   `01_Vision.md` - Established the North Star of "Zero preventable harm from medication mismanagement."
*   `02_problem2.md` - Defined the core systemic issues: cognitive burden, fragmented communication, and clinical invisibility.
*   `03_ProductGoals.md` - Established long-term strategic outcomes mapped to the core problems.
*   `04_ProductPrinciples.md` - Created the Product Constitution including Safety First and Privacy by Design.
*   `Sprint1_ArchitectureReview.md` - Completed an independent audit of the foundational artifacts.
*   `Sprint1_ResolutionPlan.md` - Established a mitigation plan for identified architectural risks.
*   `Sprint1_ExecutiveFreezeAssessment.md` - Officially reviewed and locked the foundation.
*   `Sprint1_Freeze.md` - Documented all executive decisions and governance rules for Version 1.0.

### Changed
*   **Regulatory Positioning:** Removed all language in `01_Vision.md` and `03_ProductGoals.md` implying the ability to "predict medical emergencies." Repositioned the product to "identify adherence risks" to definitively avoid FDA Software as a Medical Device (SaMD) classification.

### Removed
*   N/A (Initial Release)

### Deferred
*   Provider Financial Incentives deferred to Phase 2/3.
*   Data Liquidity / EHR API constraints deferred to Phase 2.
*   IoT Hardware Partnership governance deferred to Phase 2.

### Known Risks
*   **Adoption Risk:** If the UI introduces clinical friction for providers, they will not adopt the adherence monitoring tools.

### Approval History
*   **Sprint 1 Approved By:** Enterprise Product Governance Board
*   **Date:** 2026-07-05
*   **Status:** FROZEN

---

## Appendix: Original Generation Prompt

*The following prompt was used to generate this document.*

<details>
<summary>Click to view the original prompt</summary>

```text
# ROLE
You are an Enterprise Product Discovery Auditor, Product Governance Consultant, Enterprise Architect, and Product Methodology Reviewer.
You have over 20 years of experience designing Product Discovery Frameworks used by Fortune 500 companies, healthcare enterprises, and large-scale SaaS organizations.
Your responsibility is NOT to generate new product ideas.
Your responsibility is to review, consolidate, validate, and finalize the entire Product Discovery Framework before the project proceeds to the next phase.
Think like a Product Governance Board preparing a product foundation that will be used for many years.

---

# CONTEXT
We have completed Sprint 1 of an Enterprise Product Discovery process for a Medication Management Ecosystem.
The following artifacts are already approved and considered immutable unless a critical issue is discovered.
✓ 01_Vision.md
✓ 02_Problem.md
✓ 03_ProductGoals.md
✓ 04_ProductPrinciples.md
✓ Sprint1_ArchitectureReview.md
✓ Sprint1_ResolutionPlan.md
✓ Sprint1_Freeze.md
Treat these artifacts as the official source of truth.
Do NOT redesign the product.
Do NOT introduce features.
Do NOT rewrite the strategy.
Your task is to review the PRODUCT DISCOVERY FRAMEWORK itself.

---

# PRIMARY OBJECTIVE
Perform a Framework Consolidation Sprint.
Your mission is to ensure that Sprint 1 is completely enterprise-ready.
Review not only the documents, but also the methodology, governance, workflow, versioning, traceability, and long-term maintainability.
The result should be a framework that could be reused for future Healthcare, SaaS, ERP, FinTech, or Enterprise products.

---

# IMPORTANT RULES
Do NOT rewrite documents unless absolutely necessary.
Only recommend the minimum required changes.
If something belongs to a later phase, explicitly defer it.
Avoid unnecessary wording improvements.
Focus only on issues that affect:
• Governance
• Consistency
• Enterprise readiness
• Maintainability
• Regulatory safety
• Product discovery methodology

---

# REVIEW CHECKLIST
Review the entire framework using the following categories.

---
## 1. Workflow Validation
Validate that the workflow is logical.
Vision
↓
Problem
↓
Goals
↓
Principles
↓
Success Metrics
↓
Stakeholder Discovery
↓
Ecosystem Discovery
↓
Human Discovery
↓
Product Definition
↓
Architecture
↓
Delivery
Confirm there are no missing phases.

---
## 2. Phase Validation
Verify that every artifact belongs to the correct phase.
Specifically verify:
Is SuccessMetrics still part of Phase 1?
Does Phase 2 begin only after Phase 1 is completely closed?
Identify any incorrect phase transitions.

---
## 3. Artifact Dependency Validation
Verify every artifact correctly depends on previous artifacts.
Ensure:
Vision governs Problem.
Problem governs Goals.
Goals govern Principles.
Principles govern future decisions.
Freeze governs every future artifact.
Every dependency should be explicit.

---
## 4. Governance Validation
Review governance rules.
Determine whether additional governance is required for:
Versioning
Reviews
Approvals
Freeze rules
Traceability
Future modifications
If governance is already sufficient, state so.

---
## 5. Regulatory Validation
Confirm the framework no longer accidentally positions the product as Software as a Medical Device (SaMD).
Confirm that:
The platform supports healthcare professionals.
The platform does NOT replace clinical judgement.
The platform identifies adherence risks.
The platform enables care coordination.
The platform does NOT diagnose.
The platform does NOT predict emergencies.
The platform does NOT make autonomous clinical decisions.
If this boundary is not explicitly documented, recommend exactly where one sentence should be added.

---
## 6. Terminology Validation
Review terminology consistency.
Ignore cosmetic wording differences unless they create strategic confusion.
Do NOT recommend unnecessary find-and-replace operations.

---
## 7. Documentation Validation
Determine whether the framework is missing any enterprise governance artifacts.
Examples:
CHANGELOG.md
Phase1_Retrospective.md
FrameworkGovernance.md
FrameworkReview.md
FrameworkRoadmap.md
Only recommend artifacts that genuinely increase long-term maintainability.

---
## 8. Framework Reusability Validation
Evaluate whether this discovery methodology could be reused for:
Healthcare
SaaS
ERP
FinTech
AI Products
Enterprise Platforms
If not,
recommend the minimum improvements required.

---
## 9. Maintainability Validation
Review whether future teams could understand:
why decisions were made,
what was deferred,
what is frozen,
what can still change.
If anything is unclear,
recommend improvements.

---
## 10. Final Enterprise Readiness Assessment
Provide scores for:
Workflow
Governance
Traceability
Versioning
Maintainability
Scalability
Enterprise Readiness
Framework Reusability

---
# REQUIRED OUTPUT
Generate ONLY the following documents.
---
## 1.
FrameworkReview.md
Summarize the complete framework review.
---
## 2.
FrameworkResolutionPlan.md
List only issues that truly require action.
Ignore cosmetic issues.
Separate:
Must Fix
Recommended
Deferred
Ignore
---
## 3.
CHANGELOG.md
Generate Version 1.0.
Include:
Added
Changed
Removed
Deferred
Known Risks
Approval History
---
## 4.
Phase1_Retrospective.md
Include:
What went well
What was difficult
Key decisions
Lessons learned
Recommendations for future phases
---
## 5.
FrameworkGovernance.md
Define:
Review workflow
Approval workflow
Freeze workflow
Versioning rules
Change management
Traceability requirements
---
## 6.
FrameworkRoadmap.md
Describe the complete discovery methodology.
Show every phase.
Show every artifact.
Show dependencies.
Show review gates.
Show freeze gates.
Show completion criteria.

---
# FINAL VERDICT
At the end provide one executive recommendation.
Choose ONLY one:
A. Framework Approved
B. Framework Approved with Minor Changes
C. Framework Requires Major Revision
If approved,
state whether Sprint 1 should remain frozen and whether the team is officially authorized to continue with:
05_SuccessMetrics.md
without reopening Sprint 1.
```
</details>
